Bleichrodt H, Quiggin J. Life Cycle Preferences over Consumption and Health: When is Cost Effectiveness Analysis Equivalent to Cost Benefit Analysis? J Health Econ 1999; 18: 681-708.
Bleichrodt H, Rijn J van, Johannesson M. Probability Weighting and Utility Curvature in QALY Based Decision Making. J Math Psychol 1999; 43: 238-60.
Brouwer WBF, Exel NJA van, Koopmanschap MA, Rutten FFH. The valuation of informal care in Economic Appraisal; a consideration of individual choice and societal costs of time. Int J Technol Assess Health Care 1999; 15: 147-60.
Brouwer WBF, Hermans HEGM. Private clinics for employees as a Dutch solution for waiting lists: economic and legal aspects. Health Policy 1999; 47: 1-17.
Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999; 48: 13-27.
Brouwer WBF, Schut FT. Priority care for employees: a blessing in disguise? Health Econ 1999; 8: 65-73.
Burger H, de Laet CE, Weel A, Hofman A, Pols HAP. Added value of bone mineral density in hip fracture risk scores. Bone 1999; 25: 369-74.
Busschbach JJV, Berg Jvd, Bruggeling A, Bruijninckx, Helderman P, Hoeijenbos M, Ruiter Md, Vliet EJv. Wie extra betaalt kan eerst. Een markt voor voorrang in de zorg. Medisch Contact 1999; 54: 1660-2.
Busschbach JJV, Heerkens HM, Moleman AHF, Oostveen JPM, Stoppelenburg A, Treples RMPM, Vrakking AM. Rechtvaardigheid niet altijd synoniem met gelijkheid. Het maatschappelijk draagvlak voor bedrijvenpoli’s. Medisch Contact 1999; 54: 235-6.
Busschbach JJV, McDonnell J, Essink-Bot ML, van Hout BA. Estimating parametric relations between health description and health valuation with an application to the EuroQol instrument. J Health Econ 1999; 18: 551-71.
Busschbach JJV, McDonnell J, Tangelder MJD, Eikelboom BC, Buskens E, Algra A, Lawson JA, for the Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. EuroQol values for economic modelling quality of life after infrainguinal bypass surgery, a rectification. J Vasc Surg 1999; 30: 1162-3.
Drummond M, Dubois D, Garattini L, Horrisberger B, Jönsson B, Kristiansen I, Le Pen C, Pinto C, Poulsen P, Rovira J, Rutten F, Von der Schulenburg M, Sintonen H. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health 1999; 2: 232-332.
Van Enckevort PJ, Ten Vergert EM, Kingma J, Koëter GH, Rutten FFH. Factors to consider when designing phase III clinical trials involving economic evaluations. Percept Mot Skills 1999; 89: 1059-72.
Van Enckevort PJ, Ten Vergert EM, Geertsma A, Van der Bij W, De Boer WJ, Rutten FFH. Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. J Heart Lung Transplant 1999; 18: 496-497.
Van Enckevort PJ, Ten Vergert EM, Schrantee S, Rutten FFH, De Vries EGE. Basic concepts of economic evaluation. Crit Rev Oncol Hematol 1999;32:113-124.
Goossens MEJB, Evers SMAA, Vlaeyen JWS, Rutten-van Mölken MPMH, Van der Linden SMJP. Principles of economic evaluation for interventions of chronic musculoskeletal pain. Eur J Pain 1999; 3: 343-53.
Goossens MEJB, Vlaeyen JWS, Rutten-van Mölken MPMH, Linden SMJP van der. Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 1999; 80: 365-75.
Grijseels EWM, Goes ES, Quarles van Ufford MA, Van Hout BA. Passende medische zorg; de waarde van kosten effectiviteit, Medisch Contact, 1999; 38: 1285-6.
Groener MGH, Ineveld BM van, Byttebier G, Hout BA van, Rutten FFH. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999; 10: 283-8.
Van Hout BA, Goes ES, Grijseels EW, van Ufford MA. Economic evaluation in the field of cardiology: theory and practice. Prog Cardiovasc Dis 1999; 42: 167-73.
Kole-Snijders AMJ, Vlaeyen JWS, Goossens MEJB, Rutten-van Mölken MPMH, Heuts PHTG, Breukelen G, van Eek H. Chronic low back pain: what does cognitive coping skills training add to operant behavioral treatment? Results of a randomized clinical trial. J Consult Clin Psychol 1999; 67: 931-44.
De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Incremental cost of medical care after hip fracture and first vertebralfracture: the Rotterdam study. Osteoporos Int 1999; 10: 66-72.
Van Lent-Evers NA, Mathot RA, Geus WP, Hout BA van, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing faminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63-73.
Middelman KFG, Busschbach JJV, Koorneef M, Scholten GRM. Waarom niet de sportarts? Medisch Contact 1999; 54: 912-5.
Van Os N, Niessen LW, Casparie AF, Van Hout BA. Cost-effectiveness analysis of national clinical guidelines. Diabetes 1999; 48: 1838.
Van Rijkom J, Leufkens H, Crommelin D, Rutten F, Broekmans A. Assessment of biotechnology drugs: what are the issues? Health Policy 1999; 47: 255-274.
Rutten FFH, Grijseels EWM. De voorwaarden voor invoering en financiering van nieuwe technieken. Ned Tijdschr Geneeskd 1999; 143: 2229-32.
Rutten-van Mölken MPMH, Postma MJ, Joore MA, Van Genugten M, Leidl R, Jager JC, Feenstra T. Current and future health care impact of asthma and COPD in The Netherlands. Resp Med 1999; 93: 779-87.
Rutten-van Mölken MPMH, Roos B, Van Noord JA. An empirical comparison of the St Georges Respiratory Questionnaire and the Chronic Respiratory Questionnaire in a clinical trial setting. Thorax 1999; 54: 995-1003.
Serruys PW, Unger F, van Hout BA, van den Brand MJ, van Herwerden LA, van Es GA, Bonnier JJ, Simon R, Cremer J, Colombo A, Santoli C, Vandormael M, Marshall PR, Madonna O, Firth BG, Breeman A, Morel MA, Hugenholtz PG. The ARTS study (Arterial Revascularization Therapies Study). Semin Interv Cardiol 1999; 4: 209-19.
Tangelder MJD, McDonnell J, Busschbach JJV, Buskens E, Algra A, Lawson JA, Eikelboom BC on behalf of the Dutch BOA Study Group. Quality of life after infrainguinal bypass surgery. J Vasc Surg 1999; 29: 913-9.
Uyl-de Groot CA, Ossenkoppele GJ, Buijt I, Huijgens PC. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin’s lymphoma. Pharmacoeconomics 1999; 15: 305-11.
Uyl-de Groot CA, Ossenkoppele GJ, Buyt I, Huygens PC. Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995. J Hematother Stem Cell Res 1999; 8: 619-25.
Van der Woude T, Rutten-van Mölken MPMH, Buller HR, Brandjes DPM. Rentabilité de l’utilisation a titre prophylactique des bas de compression chez des patients presentant une thrombose veineuse profonde (The cost-effectiveness of the prophylactic uses of compression stockings in patients with deep-vein thrombosis) Phlébologie 1999; 52: 145-52.